Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma

INTRODUCTION: The AXIS trial established axitinib as a standard of care treatment for patients with metastatic renal cell carcinoma (mRCC) after failure of a prior tyrosine kinase inhibitor. Axitinib dosing begins at 5  mg twice daily, with escalation of doses to 7  and 10  mg after consecutive 2-we...

Descripción completa

Detalles Bibliográficos
Autores principales: Doherty, Gary Joseph, Lynskey, Deirdre, Matakidou, Athena, Fife, Kate, Eisen, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241974/
https://www.ncbi.nlm.nih.gov/pubmed/30498581
http://dx.doi.org/10.1136/esmoopen-2018-000445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241974/
https://www.ncbi.nlm.nih.gov/pubmed/30498581
http://dx.doi.org/10.1136/esmoopen-2018-000445

Ejemplares similares